

June 26, 2020

To,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.
Fax : 022-22723121

To,
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra – Kurla Complex,
Bandra (East), Mumbai – 400 051.
Fax: 022 -26598237/38

Dear Sir/Madam,

Ref.:- Scrip Code -532908

Scrip ID-SHARONBIO

Sub: Disclosure of material impact of Covid-19 pandemic

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read together with the SEBI circular dated SEBI Circular No. SEBI/HO/CFD/CMDI/CIR/P/2020/84 dated 20 May 2020 on disclosure of material impact of COVID 19 pandemic on listed companies under, we wish to inform you of the following:

- In view of the continuing lockdown situation due to COVID-19 pandemic across the country, the Company has monitored the impact of COVID-19 on all aspects of its business, particularly for the financial year 2020-2021. There has been no significant impact on the business and profits of the Company for the year ended March 31, 2020. The Company is in manufacturing and sale of essential products.
- However, due to shortage of labour and manpower as well as the ambiguity for allowing operations; Company could not operate manufacturing activities for most part of April at all its locations. As of date, manufacturing activities have reached near optimum production and in execution of orders in hand, both domestic and exports. The impact of order execution capability resulted in lower revenue in the first quarter.
- The company has exercised due care, in concluding on significant accounting judgements and estimates, recoverability of receivables, assessment of inventory & other financial assets, based on internal & external information as available, up to the date of approval of these financial results. In view of the continued uncertainties and its inability to predict the extend and duration of Covid-19 situation, the impact assessed may be different from the estimates made as at the date of approval of these financial results and management will continue to monitor any



Caring for relationships

material changes arising due to the impact of this pandemic on financial and operational performance of the company and take necessary measures to address the situation.

This is for your information and record.

Thanking You,

Yours faithfully,

For **Sharon Bio-Medicine Limited**


Kaushik Banerjee
Chief Executive Officer

